Compare Quest Diagnostics Inc (DGX) vs Mercadolibre Inc (MELI) Price & Performance

Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.

The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.

MercadoLibre (MELI) trades at $1,889.85, up 0.91% on the day, with a bullish technical signal and strong analyst support. Revenue grew to $28.89 billion in 2025, though net income margin dipped to 6.91%. The company is expanding its fintech ecosystem, with credit portfolio surging 75% to $16.4 billion in Q2 2026. Operating cash flow remains robust at $12.12 billion, supporting aggressive investment in logistics and market expansion across Latin America.

Outlook is positive given dominant market position and integrated e-commerce-fintech model, but valuation multiples like P/E of 50.51 suggest high growth expectations. Risks include macroeconomic pressures in key markets like Argentina and intense regional competition. Analyst consensus is strongly bullish with a $2,170 price target, indicating ~15% upside from current levels.